SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C.  20549

FORM 6-K
 
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 OF
THE SECURITIES EXCHANGE ACT OF 1934
 
For the month of February 2019
 

BioLineRx Ltd.
(Translation of registrant’s name into English)
 

2 HaMa’ayan Street
Modi’in 7177871, Israel
(Address of Principal Executive Offices)
 
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F ☒       Form 40-F   ☐
 
Indicate by check mark whether the registrant by furnishing the information contained in this form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934:
 
Yes ☐   No  ☒


On February 5, 2019, the registrant issued the press release which is filed as Exhibit 1 to this Report on Form 6-K.
 


 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
  BioLineRx Ltd.  
       

By:
/s/ Philip Serlin  
    Philip Serlin  
    Chief Executive Officer  
       
Dated: February 5, 2019
 



BioLineRx (NASDAQ:BLRX)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more BioLineRx Charts.
BioLineRx (NASDAQ:BLRX)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more BioLineRx Charts.